Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Stock Information for Hepion Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.